Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Swine Vaccines Market Size & Share 2026-2035
Report ID: GMI10445
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Swine Vaccines Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Swine Vaccines Market Size
The swine vaccines market was valued at USD 1.6 billion in 2025 and is projected to reach USD 2.9 billion by 2035, expanding at approximately 6.3% from 2026 to 2035.
Swine Vaccines Market Key Takeaways
Market Leader: Merck led with over 38.5% market share in 2025.
Leading Players: Top 5 players in this market include Zoetis, Boehringer Ingelheim International, Merck, Ceva, Elanco Animal Health Incorporated, which collectively held a market share of 95% in 2025.
Demand is anchored in the economic exposure created by infectious disease in intensive pork production, where preventive vaccination protects herd performance, reduces treatment disruption, and supports predictable supply planning. Iowa State University analysis has estimated that porcine reproductive and respiratory syndrome (PRRS) alone caused roughly USD 1.2 billion in annual U.S. pork-production losses during 2016–2020, illustrating the financial consequence of persistent endemic disease [1]Iowa State University College of Veterinary Medicine, Institutional veterinary and swine-health research, 2021, vetmed.iastate.edu.
Disease-control requirements are widening geographically. African swine fever (ASF) had been reported by 83 countries as of January 2025, and its acute form can cause mortality of up to 100% [2]World Organisation for Animal Health, African swine fever, January 2025, woah.org. Although ASF prevention also relies heavily on surveillance, movement controls, and farm biosecurity, its spread raises the value placed on veterinary prevention infrastructure and pathogen-specific vaccine innovation. The commercial need is amplified by pork's role in food supply; WOAH cites pork as accounting for more than 35% of global meat intake.
The underlying livestock demand base remains supportive. OECD-FAO projects global pork demand to rise from an average of 110.5 million tons in 2019–2021 to 128.9 million tons by 2031, with Asian demand increasing from 61.4 million tons to 76 million tons over the same period. This shifts vaccine purchasing from a narrow disease-response expense toward an input tied to production continuity, reproductive management, and the ability to meet processor and food-security requirements.
GMI Analyst View
We estimate that the market's movement from USD 1,578.2 million in 2025 to USD 2,876.1 million in 2035 reflects more than routine herd expansion. PRRS-related U.S. production losses and the global reach of ASF expose producers to losses that can exceed the immediate cost of vaccination, while OECD-FAO's projected increase in pork consumption enlarges the production base requiring preventive health management. Suppliers with demonstrable protection against economically consequential swine pathogens, reliable herd-level service capability, and scalable manufacturing are therefore better positioned than suppliers competing primarily on unit price.
Key Drivers
Rising incidence of zoonotic diseases
The disease burden affecting swine production strengthens the commercial case for preventive herd-health programs. ASF's occurrence across 83 countries and its potential for extreme mortality make outbreak preparedness a supply-chain issue as much as a veterinary issue. Vaccination demand is shaped not only by a pathogen's direct clinical effect, but also by the operational cost of movement restrictions, depopulation risk, interrupted breeding cycles, and delayed market access.
Expanding livestock industry and food security concerns
Rising pork consumption increases the economic value at risk within commercial swine systems. OECD-FAO expects Asian pork demand to grow by 24% by 2031, creating a larger installed base of animals and production sites requiring disease prevention. Producers and integrators facing higher throughput requirements have greater incentive to maintain vaccination protocols that reduce performance volatility and protect reproductive output.
Advancements in vaccine technology
Product development is increasingly focused on minimizing administration burden while broadening pathogen coverage. Merck Animal Health's Sequivity platform uses RNA particle technology to create herd-specific prescription vaccines within an indicated 10–16-week development window, showing how platform technologies can address evolving disease challenges at farm level. Combination products, custom-vaccine platforms, and emerging mRNA approaches can improve the value proposition where producers seek fewer handling events, broader coverage, or faster adaptation to herd-specific pathogen profiles.
AI and generative-AI tools may support this transition by helping developers organize pathogen surveillance data, prioritize antigen candidates, and manage documentation workflows. Their market effect depends on validation, regulatory acceptance, and integration with veterinary decision-making rather than on software deployment alone.
Increasing outbreaks of animal diseases
Outbreaks can accelerate vaccine adoption where disease-control costs become visible at farm level. WOAH identifies biosecurity, surveillance, early detection, and movement control as essential components of ASF prevention, indicating that vaccines operate within a wider risk-management system rather than as a stand-alone intervention. Suppliers that connect vaccine protocols with diagnostic support, administration guidance, and biosecurity planning can become more embedded in producer disease-management programs.
Key Restraints
High R&D costs & long development timelines
Swine-vaccine development requires pathogen characterization, safety and efficacy work, manufacturing validation, and jurisdiction-specific regulatory documentation. These requirements raise the cost of pursuing products for fragmented disease needs or smaller regional markets. The interval between regulatory licensing and commercial availability can also affect launch economics; Merck received a U.S. license for Circumvent CML in 2022 before announcing market availability in June 2023.
Cold chain infrastructure limitations
Veterinary biologics depend on controlled storage and distribution conditions, creating a practical adoption barrier where rural logistics, clinic storage capacity, or last-mile delivery systems are inconsistent. The constraint is particularly relevant in regions where herd expansion is occurring outside established integrator networks. Thermostable formulations and distribution models that reduce temperature sensitivity could improve access, but such improvements must preserve antigen stability and regulatory compliance.
Regulatory complexity & approval delays
Veterinary vaccine authorization requires evidence that the product's quality, safety, and efficacy are appropriate for its intended use. The European Medicines Agency's assessment and authorization process for Cirbloc M Hyo demonstrates the formal pathway required for combination swine vaccines entering the EU market. Regulation protects product quality, but varying data expectations and approval timelines can delay product availability, particularly for technologies designed to address changing pathogen profiles.
GMI Analyst View
Our assessment suggests that the approximately 6.3% growth trajectory remains achievable because disease losses and expanding pork production create recurring demand, yet growth will not be uniform across geographies. Cold-chain capability and regulatory capacity are most likely to constrain uptake in markets where disease risk is high but veterinary distribution networks remain uneven. The European authorization of Cirbloc M Hyo illustrates that regulatory rigor can support confidence in combination products, while also raising the development threshold for smaller or less capitalized entrants. The commercial advantage therefore lies with suppliers that pair differentiated antigens with validated distribution, regulatory resources, and producer-facing implementation support.
Swine Vaccines Market Segment Analysis
By Type
Inactivated/killed vaccines generated USD 908 million in 2025, reflecting their established role in programs where safety, formulation stability, and compatibility with structured herd-health protocols are decisive. Their broad use in commercial production does not eliminate the need for innovation; instead, it provides a large installed base for differentiated combinations and improved delivery formats.
Live attenuated vaccines accounted for 34.5% of the market in 2025 and are projected to expand at approximately 6.6% CAGR. Their role is strongest where immune-response characteristics and disease-control objectives justify their use. Viral vector vaccines, mRNA vaccines, and other vaccine types remain important development areas, particularly where manufacturers seek faster antigen adaptation or improved targeting of emerging pathogen strains. Adoption of these platforms will depend on evidence generation, manufacturing scalability, and acceptance within veterinary practice.
By Application
Viral infections represented 66.2% of the market in 2025 and are projected to grow at approximately 6.4% CAGR. PRRS, porcine circovirus-associated disease, and ASF-related biosecurity concerns illustrate why viral disease management remains central to swine-vaccine purchasing decisions. Bacterial infections continue to support demand for vaccines targeting respiratory and enteric pathogens, while parasitic infections and other applications address more specialized herd-health requirements.
The application mix favors products that reduce the operational complexity of protecting against multiple economically relevant pathogens. Combination vaccines can be especially valuable where respiratory, reproductive, or enteric disease challenges overlap within the same production system.
By Route of Administration
Injection vaccines generated USD 1.2 billion in 2025 and are projected to reach USD 2.2 billion by 2035. Their market position reflects established veterinary protocols, dose control, and compatibility with multi-antigen products. Injectable formats can, however, add labor and animal-handling demands, particularly in large-scale facilities.
Oral vaccines are projected to grow at approximately 6.6% CAGR, supported by their potential to reduce handling intensity and facilitate delivery across large groups. Immersion/spray vaccines remain relevant for applications where flock- or group-level administration fits the production workflow. Route selection ultimately depends on pathogen biology, age of animals, facility practices, labor availability, and the level of administration precision required.
By Distribution Channel
Veterinary hospital pharmacies held 77.1% of the market in 2025, reflecting the importance of veterinary oversight, prescription management, storage conditions, and protocol design in swine vaccination. Retail pharmacies provide an additional supply channel where products and regulations permit, but their role is more limited for vaccines requiring specialized handling or veterinary guidance.
E-commerce is projected to grow at approximately 6.8% CAGR. Its expansion is likely to be strongest where digital ordering can complement, rather than replace, veterinary authorization, cold-chain fulfillment, and traceable delivery. Online access alone does not resolve the practical requirements of biologics distribution.
GMI Analyst View
Our primary research with practicing veterinarians indicates that disease threat and perceived vaccine efficacy remain central to swine-health decisions. When considered alongside the USD 908 million inactivated/killed vaccine segment and the 34.5% share held by live attenuated products in 2025, the evidence points to a market in which established platforms retain substantial value while combination and adaptable technologies redefine where incremental growth occurs. The recent introduction of dual- and multi-antigen products supports this interpretation: value is migrating toward solutions that reduce intervention complexity while addressing overlapping pathogen exposure. Suppliers pursuing mRNA, RNA-particle, or other next-generation platforms will need to demonstrate operational gains that matter to veterinarians and producers, not merely technological novelty.
Swine Vaccines Market Regional Analysis
North America
North America generated USD 682.6 million in 2025 and is projected to reach USD 1,189.2 million by 2035, growing at approximately 5.8% CAGR. The region's large installed production base supports vaccine demand: USDA inventory data indicate that the United States has more than 70 million hogs [4]U.S. Department of Agriculture National Agricultural Statistics Service, Hogs and Pigs, nass.usda.gov. Established integrator systems, veterinary networks, and regulatory infrastructure favor structured vaccination protocols and support commercial adoption of combination and premium products.
The U.S. market was valued at USD 635.4 million in 2025, compared with USD 606 million in 2024, USD 578.7 million in 2023, and USD 553.3 million in 2022. Recent U.S. product activity, including Merck's Circumvent CML and Boehringer Ingelheim's INGELVAC CIRCOFLEX AD, demonstrates continued investment in multi-pathogen and genotype-focused protection, [5]Boehringer Ingelheim, Boehringer launches swine vaccine with advanced protection against PCV2, September 3, 2025, boehringer-ingelheim.com.
Europe
Europe generated USD 430.2 million in 2025. The region's relevance rests on its substantial pork-production base; the European Commission estimates that Europe produces approximately one-fifth of global pork output. Demand is shaped by mature herd-health practices, regulatory scrutiny, disease-control requirements, and product differentiation through combination vaccines.
Germany, the UK, France, Spain, Italy, and the Netherlands represent important markets within the regional production and veterinary-health landscape. The EU authorization of Ceva's Cirbloc M Hyo, as well as Virbac's 2025 French launch of a combined porcine parvovirus and leptospirosis vaccine, indicate continued commercial emphasis on respiratory and reproductive disease management.
Asia Pacific
Asia Pacific is projected to record approximately 7% CAGR through 2035, the fastest regional expansion rate. OECD-FAO forecasts Asian pork demand to increase from 61.4 million tons to 76 million tons by 2031, expanding the scale of production requiring disease-management investment. China, India, Japan, Australia, and South Korea each contribute distinct demand conditions based on production structure, disease exposure, regulatory practice, and veterinary distribution capacity.
ASF remains a defining regional risk factor. China reported Asia's first occurrence of ASF in August 2018, and the subsequent geographic spread has elevated the importance of surveillance, biosecurity, and coordinated disease-control capability. Faster growth in the region does not automatically translate into easier market entry: suppliers must adapt to infrastructure variation, local registration requirements, and the differing capacity of commercial and smallholder production systems to implement vaccine protocols.
Latin America
Brazil, Mexico, and Argentina provide a meaningful swine-production base, with vaccine demand influenced by export-oriented production, farm consolidation, and disease-management requirements. The commercial opportunity is stronger where veterinary access, refrigeration capability, and producer economics support consistent preventive programs. Disease outbreaks can accelerate demand, although procurement may remain sensitive to price and local distribution coverage.
Middle East and Africa
South Africa and the UAE represent the principal country scope within the Middle East and Africa. ASF's continuing presence across multiple African countries reinforces the importance of prevention, surveillance, and movement-control systems. Market development is constrained by variable cold-chain infrastructure and uneven access to specialized veterinary services, making locally resilient distribution and technical support essential to sustained adoption.
GMI Analyst View
In our view, North America's USD 682.6 million market value in 2025 reflects the depth of its commercial herd base, established veterinary channels, and capacity to absorb higher-value combination products, while Asia Pacific's approximately 7% growth outlook is driven by a larger incremental demand base and greater disease-control urgency. U.S. inventory exceeding 70 million hogs supports recurring protocol-driven demand, whereas projected Asian pork-demand growth and ASF's regional history make prevention capability a more immediate capacity issue. Europe presents a different strategic case: its large pork-production role and formal authorization environment reward suppliers able to meet regulatory standards and demonstrate clear value in respiratory and reproductive disease control.
Swine Vaccines Market Share & Competitive Landscape
The market is concentrated, with the top five participants estimated to account for approximately 95% of global revenue. Scale matters because leading suppliers can fund antigen research, regulatory submissions, manufacturing validation, cold-chain distribution, and veterinary technical support across multiple regions. Competition is therefore driven by portfolio breadth and execution capability as much as by the presence of a single vaccine product.
The competitive scope includes Addison Biological Laboratory, Bioveta, Boehringer Ingelheim, Ceva Santé Animale, Colorado Serum Company, Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals, Merck Animal Health, Biogénesis Bagó, Vaxxinova (EW Group), Vibac, and Zoetis. Large multinational suppliers compete through broad swine-health portfolios, technical service networks, and product-development capacity, while regional and specialized manufacturers can compete through local registration knowledge, targeted pathogen coverage, and proximity to producer channels.
Boehringer Ingelheim, Ceva Santé Animale, and Merck Animal Health illustrate the direction of product competition through multi-antigen and disease-specific innovation. The strategic significance of combination vaccines is not simply broader label coverage; a single administration can reduce handling requirements, simplify protocol design, and improve compliance in intensive production systems when clinical protection is aligned with the herd's disease profile, [6]European Medicines Agency, Cirbloc M Hyo EPAR, September 13, 2024, ema.europa.eu.
Smaller participants face a more selective path to differentiation. Addison Biological Laboratory, Bioveta, Colorado Serum Company, Indian Immunologicals, Biogénesis Bagó, Vaxxinova (EW Group), and Vibac can benefit where local disease patterns, channel access, or market-specific requirements favor specialized product offerings. Elanco Animal Health Incorporated, HIPRA S.A., and Zoetis remain positioned to compete through veterinary relationships, portfolio capability, and investment in swine-health services. Pricing considerations will remain tied to the cost of disease risk, product breadth, veterinary involvement, and logistics rather than vaccine price alone.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →